Artrya (ASX:AYA) has secured a three-year commercial agreement with Sonic Healthcare for the Salix Coronary Anatomy platform (Salix).
Artrya is a medical technology company that commercialises the patented Salix artificial intelligence platform, which detects key coronary artery disease imaging markers.
Salix is designed to enhance accuracy and efficiency in detecting stenoses and other critical markers, including high-risk plaque from CCTA scans, whilst also optimising clinical workflow.
The company said the contract with Sonic would generate revenue through a subscription model. The company anticipates initial revenue in the fourth quarter of the financial year 2025.
As Australia's second-largest radiology diagnostic imaging group, Sonic manages over 125 radiology centres and boasts a network of 1,800 radiologists and pathologists, supported by more than 17,000 medical scientists, radiographers, sonographers, technicians, and nurses.
Under the agreement, Salix will be integrated into all Sonic Healthcare Radiology centres that perform Coronary Computed Tomography Angiography (CCTA) scans for coronary heart disease detection.
Artrya CEO Mathew Regan said, “Our contract with Sonic is a significant milestone for our commercial growth in Australia. We are thrilled to partner with a globally leading healthcare provider who is also Australia’s second largest radiology group, placing our lifesaving, AI-driven technology in the hands of Australian clinicians to improve the diagnosis of the world’s number one killer, heart disease.
The CEO of Sonic Healthcare Australia - Radiology, Dr Julian Adler, said, “We are proud to incorporate Salix as part of our first-line process for cardiovascular care. Salix offers an evidence-based, personalised approach to the imaging of patients at risk for coronary vascular disease. Importantly, Salix provides a rapid, full assessment of the coronary arteries at the point of care, thus supporting our skilled cardiovascular imaging specialists and significantly improving the diagnostic workflow for our patients and their referrers. Artyra’s technology enhances the standard of care for the non-invasive diagnosis of coronary artery disease.”
